Every Form 4 that Marker Therapeutics, Inc. (MRKR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRKR filings page.
Marker Therapeutics, Inc. (MRKR) disclosed that director Katharine Knobil received new stock option grants under the company's 2020 Omnibus Stock Ownership Plan. On November 17, 2025, she was granted options to buy 84,411 shares of common stock at an exercise price of $0.9548 per share for her remaining 2024 director service, in addition to 30,000 options previously granted on February 12, 2025. She also received a separate grant of stock options for 137,330 shares of common stock at the same exercise price for her 2025 director service. All of these options vest on the anniversary of the grant date and are held directly.
Marker Therapeutics, Inc. (MRKR) reported that director Norman David Eansor received new stock option awards. On 11/17/2025, he was granted options to purchase 84,411 shares of common stock at an exercise price of $0.9548 per share under the company’s 2020 Omnibus Stock Ownership Plan, representing the remaining options for his service as a director for 2024. These options vest on the anniversary of the grant date and expire on 11/17/2035.
On the same date, he was also granted options to purchase an additional 137,330 shares of common stock at an exercise price of $0.9548 per share for his service as a director for 2025. These options have the same vesting schedule and expiration date of 11/17/2035 and are held as direct ownership.
Marker Therapeutics director Steve Elms reported new stock option awards for board service. On 11/17/2025, he received stock options to buy 84,411 shares of common stock at an exercise price of $0.9548, representing remaining options for his 2024 director compensation under the 2020 Omnibus Stock Ownership Plan; 30,000 shares had previously been granted on February 12, 2025. On the same date, he also received options for 137,330 shares for his 2025 director service, also at $0.9548 per share. Both grants vest on the anniversary of the grant date and expire on 11/17/2035, and are held as direct ownership.
Marker Therapeutics (MRKR) filed a Form 4 reporting a director stock option grant. The filing shows a stock option (right to buy) for 147,611 shares at an exercise price of $0.9877, granted on 10/31/2025 under the company’s 2020 Omnibus Stock Ownership Plan. The options vest in 36 equal monthly installments, subject to continued board service, and expire on 10/31/2035. Following the transaction, 147,611 derivative securities are beneficially owned, held directly.
Marker Therapeutics (MRKR) reported an insider equity award. A Form 4 discloses that Chief Executive Officer and Director Juan Vera received an employee stock option grant for 250,000 shares at an exercise price of $0.9877 per share on October 31, 2025.
Per the plan terms, 25% vests on the first anniversary of the grant date, with the balance vesting in equal annual installments over the next three years, contingent on continued service. The options expire on October 31, 2035.